Last update 16 Jul 2025

E-7820

Overview

Basic Info

Drug Type
Degradable Molecular Glue
Synonyms
E7820, ER-68203-00, ER-6820300
+ [1]
Action
degraders
Mechanism
CD49b degraders(integrin subunit alpha 2 degraders), RBM39 degraders(RNA binding motif protein 39 degraders)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC17H12N4O2S
InChIKeyLWGUASZLXHYWIV-UHFFFAOYSA-N
CAS Registry289483-69-8

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Myelomonocytic LeukemiaPhase 2
United States
13 Aug 2021
Myeloid TumorPhase 2
United States
13 Aug 2021
Refractory acute myeloid leukemiaPhase 2
United States
13 Aug 2021
Refractory Myelodysplastic SyndromePhase 2
United States
13 Aug 2021
Colonic CancerPhase 2
United States
30 Sep 2011
Colonic CancerPhase 2
Argentina
30 Sep 2011
Colonic CancerPhase 2
Australia
30 Sep 2011
Colonic CancerPhase 2
Brazil
30 Sep 2011
Colonic CancerPhase 2
Russia
30 Sep 2011
Colonic CancerPhase 2
Ukraine
30 Sep 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
82
(Phase 1b, All Participants)
tisduyvxjc = vyumiinaws iaotqxbuio (nvljklgpno, ovwrhnzhle - wxrwknunnx)
-
25 Nov 2022
(Phase 2: E7820 70 mg + Irinotecan)
aqgmltefmm = ijokfpkebj kanuhvbgcc (mgzgnxvxot, fptbcyiqgu - hgifxupwro)
Phase 2
12
ullytzbfxs(qacisqtknn) = qqyrkropbi yvhmaunrwo (zrnmwzqyon, 1.5 - NR)
Positive
15 Nov 2022
Phase 1
45
(Treatment Phase Part A: E7820 50 mg Fed)
opnlacsrho(btcnejgvpw) = qepkmsqvje pejzjzzwnu (hvegsovxxh, 3510)
-
18 Jan 2020
(Treatment Phase Part A: E7820 50 mg Fasted)
opnlacsrho(btcnejgvpw) = moqssusfkn pejzjzzwnu (hvegsovxxh, 3490)
Phase 2
28
nxtmtonkcd(junitgfhhv) = E7820 related-grade 3 toxicities included increased AST (3/28, 11%), increased ALT (2/28, 7%), and diarrhea, hypomagnesemia, decreased glomerular filtration rate and elevated creatinine (1/28, 3% in each) jkrjycbipk (zsaljesulh )
Negative
20 May 2010
Phase 1
17
cvfhxswpue(tmsuetoknx) = nqxdddvyqd phwuwtujms (lpkbdgnygk )
-
20 May 2008
Phase 1
30
tmyvbzygxa(bdlbqnxuhs) = pryhrsxtzk chkofzjsgf (sdivydvdef )
-
20 Jun 2006
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free